Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ. Gerber DE, et al. Among authors: subramaniam ds. Lung Cancer. 2018 Mar;117:44-49. doi: 10.1016/j.lungcan.2018.01.010. Epub 2018 Feb 3. Lung Cancer. 2018. PMID: 29496255 Free PMC article. Clinical Trial.
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara PN Jr. Wakelee HA, et al. Among authors: subramaniam ds. Cancer Chemother Pharmacol. 2017 May;79(5):923-932. doi: 10.1007/s00280-017-3283-z. Epub 2017 Mar 28. Cancer Chemother Pharmacol. 2017. PMID: 28352985 Free PMC article. Clinical Trial.
Emerging protein kinase inhibitors for non-small cell lung cancer.
Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalek FJ, Giaccone G. Liu SV, et al. Expert Opin Emerg Drugs. 2014 Mar;19(1):51-65. doi: 10.1517/14728214.2014.873403. Epub 2013 Dec 20. Expert Opin Emerg Drugs. 2014. PMID: 24354593 Review.
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.
Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL. Crandall JP, et al. Among authors: subramaniam ds. EJNMMI Res. 2017 Dec;7(1):8. doi: 10.1186/s13550-017-0258-3. Epub 2017 Jan 19. EJNMMI Res. 2017. PMID: 28102506 Free PMC article.
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ. Berlin J, et al. Among authors: subramaniam ds. Br J Cancer. 2018 Apr;118(7):938-946. doi: 10.1038/s41416-018-0003-3. Epub 2018 Mar 12. Br J Cancer. 2018. PMID: 29527010 Free PMC article. Clinical Trial.
BIBW 2992 in non-small cell lung cancer.
Subramaniam DS, Hwang J. Subramaniam DS, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):415-22. doi: 10.1517/13543784.2011.557063. Expert Opin Investig Drugs. 2011. PMID: 21320004 Review.
69 results